Authors

• Sonia Dolfi (ORCID: https://orcid.org/0000-0001-9454-4583)
• Carlos Gomez‐Roca (ORCID: https://orcid.org/0000-0002-8043-2529)
• Margaret K. Callahan (ORCID: https://orcid.org/0000-0002-9087-0012)
• Katriina Peltola (ORCID: https://orcid.org/0000-0002-3007-193X)
• Evan J. Lipson (ORCID: https://orcid.org/0000-0003-2976-0911)
• Ignacio Melero (ORCID: https://orcid.org/0000-0002-1360-348X)
• Paolo A. Ascierto (ORCID: https://orcid.org/0000-0002-8322-475X)
• Vanna Chiarion‐Sileni (ORCID: https://orcid.org/0000-0001-9191-9124)
• Marta Nyakas (ORCID: https://orcid.org/0000-0001-6331-3440)
• Inge Marie Svane (ORCID: https://orcid.org/0000-0002-9451-6037)
• Deepti Warad (ORCID: https://orcid.org/0000-0002-1899-5208)
• Eva Muñoz‐Couselo (ORCID: https://orcid.org/0000-0001-7556-7608)
• Jean‐Jacques Grob (ORCID: https://orcid.org/0000-0002-0667-153X)
• Charlie Garnett‐Benson (ORCID: https://orcid.org/0000-0002-0238-3303)
• James Larkin (ORCID: https://orcid.org/0000-0001-5569-9523)
• Hao Tang (ORCID: https://orcid.org/0000-0003-4653-7244)
• Reinhard Dummer (ORCID: https://orcid.org/0000-0002-2279-6906)
• Patrick Djidel
• Diane Reusser-Wolf

Institutions

• Oslo University Hospital (NO)
• Bloomberg (United States) (US)
• Royal Marsden NHS Foundation Trust (GB)
• Memorial Sloan Kettering Cancer Center (US)
• Institute of Cancer Research (GB)
• Johns Hopkins University (US)
• ZHAW Zurich University of Applied Sciences (CH)
• University of Zurich (CH)
• Aix-Marseille Université (FR)
• Helsinki University Hospital (FI)
• Herlev Hospital (DK)
• Copenhagen University Hospital (DK)
• Bristol-Myers Squibb (United States) (US)
• Institut universitaire du cancer de Toulouse Oncopole (FR)
• Istituto Oncologico Veneto (IT)
• Vall d'Hebron Hospital Universitari (ES)
• Clinica Universidad de Navarra (ES)
• Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
• Sidney Kimmel Comprehensive Cancer Center (US)
• Bristol-Myers Squibb (Switzerland) (CH)

Publication Details

Journal

Journal for ImmunoTherapy of Cancer

Published

2025-02-01

DOI

https://doi.org/10.1136/jitc-2024-009773

Citations

4

Primary Topic

Cancer Immunotherapy and Biomarkers

Type

article

Field-Weighted Citation Impact

4.18

Funders

• Amgen
• Bristol-Myers Squibb
• Eli Lilly and Company
• Pfizer
• AstraZeneca
• Sanofi
• Gilead Sciences
• Regeneron Pharmaceuticals
• Merck KGaA
• Les Laboratories Pierre Fabre
• CareDx
• Incyte
• Seagen
• Natera
• Eisai
• Novo Nordisk
• European Society for Medical Oncology
• PharmaMar
• Sun Pharma
• Ipsen
• Italfarmaco
• Genentech
• EMD Serono
• Daiichi Sankyo Europe